APDN - Applied DNA Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4004
-0.0096 (-2.34%)
As of 3:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4100
Open0.4100
Bid0.4040 x 800
Ask0.4250 x 1800
Day's Range0.3720 - 0.4400
52 Week Range0.2500 - 1.8400
Volume1,247,421
Avg. Volume403,968
Market Cap17.295M
Beta (3Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.3220
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Business Wire

    Applied DNA Extends Textiles Business to Include Global Down and Feather Supply Chain in Partnership with Industry Leader Navarpluma

    Applied DNA Sciences Inc. (APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today a sales and marketing partnership with Navarpluma that extends Applied DNA’s Textiles business to include the global down and feather supply chain1. Formalization of the partnership between the two companies follows the completion of a groundbreaking technological advance by Applied DNA to utilize its SigNature® DNA system to allow for traceability of materials in the down and feather industry. Navarpluma S.L., one of the world’s premier suppliers of down and feathers to the textile industry, will be the first to offer this new system to its customer base that counts some of the world’s most prestigious brands as clients.

  • Thomson Reuters StreetEvents

    Edited Transcript of APDN earnings conference call or presentation 13-Aug-19 8:30pm GMT

    Q3 2019 Applied DNA Sciences Inc Earnings Call

  • Business Wire

    Applied DNA Reports Fiscal Third Quarter 2019 Financial Results

    Company to Hold Conference Call and Webcast Today, Tuesday, August 13, 2019 at 4:30 PM EST.

  • Business Wire

    Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx

    LineaRx, Inc. (“LineaRx”), a majority-owned subsidiary of Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the “Company”) announced that, in a decision rendered on August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) approved chimeric antigen receptor (CAR) T-cell therapies that fit the CMS criteria for Medicare beneficiaries nationwide. LineaRx believes its unique method of manufacturing DNA is well poised to benefit from the increasing demand for nucleic-acid dependent therapies, like CAR T, as biotechnology companies pursue their gene and cell therapies with reimbursement assured by the CMS decision. CAR T-based treatments involve extracting and genetically altering a patient’s T cells to attack a protein on the surface of cancer cells.

  • Business Wire

    LineaRx Acquires Assets and Intellectual Property of Vitatex

    LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ:APDN), announced today that it has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc. (“Vitatex”), a private biotechnology company focused on advancing personalized medicine with an innovative solution that isolates Invasive Circulating Tumor Cells (iCTCs) from standard patient blood samples. Vitatex’s solution identifies metastatic cells often before primary tumors are visible to other diagnostic technologies, when preventive care for impending cancer is still an option. “We are honored to now include Vitatex executives on our team and employ its powerful technology within our platform,” said Dr. James Hayward, president and CEO of LineaRx.

  • Business Wire

    Applied DNA Signs Master Services Agreement with Schreiner Group to Deliver SigNature® DNA Labels to Protect Pharmaceutical Supply Chains

    Applied DNA products and services offer forensic, high-value differentiation for Schreiner MediPharm’s customers to secure supply chains

  • Business Wire

    Applied DNA Schedules Fiscal 2019 Third Quarter Financial Results Conference Call for Tuesday, August 13, 2019 at 4:30 PM ET

    Applied DNA Sciences, Inc. , announced today it plans to release financial results for its fiscal 2019 third quarter ended June 30, 2019 after market close on Tuesday, August 13, 2019.

  • Business Wire

    Applied DNA and TheraCann International Sign Term Sheet to Amend Licensing and Cooperation Agreement

    Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for product authenticity and traceability solutions, today announced that the Company and TheraCann International Benchmark Corporation (“TheraCann”) have signed a non-binding term sheet (the “Term Sheet”) outlining agreed-upon amendments to the exclusive licensing and cooperation agreement signed March 28, 2019 between the parties (the “Agreement”). The Term Sheet is expected to be followed by definitive contractual amendments. Under the Term Sheet, the parties agreed to amend the Agreement to provide Applied DNA with $4M in TheraCann convertible preferred stock and a $1M convertible promissory note in exchange for Applied DNA’s waiver of $4M in cash payments due from TheraCann on or before August 15, 2019.

  • How Much Of Applied DNA Sciences, Inc. (NASDAQ:APDN) Do Insiders Own?
    Simply Wall St.

    How Much Of Applied DNA Sciences, Inc. (NASDAQ:APDN) Do Insiders Own?

    Every investor in Applied DNA Sciences, Inc. (NASDAQ:APDN) should be aware of the most powerful shareholder groups...

  • Thomson Reuters StreetEvents

    Edited Transcript of APDN earnings conference call or presentation 9-May-19 8:30pm GMT

    Q2 2019 Applied DNA Sciences Inc Earnings Call

  • Business Wire

    LineaRx Ships DNA to Support Therapy Development for Neurodegenerative Diseases

    LineaRx, Inc. a wholly-owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced today that it has shipped multiple customized linear DNA amplicons to Evotec SE, a well-known therapeutic development company, to support their research efforts related to neurodegenerative diseases such as Huntington’s, Parkinson’s or Alzheimer’s disease. “Evotec SE, like a growing number of other cutting-edge biotech companies, sees value in evaluating linear DNA as a foundation for their research and recognizes the strengths of LineaRx in the design and large-scale production of linear DNA using LineaRx’s proprietary platform for DNA production by polymerase chain reaction (“PCR”).

  • Business Wire

    TheraCann Adds Blockchain Functionality to ETCH biotrace Platform Powered by Applied DNA 

    ETCH biotrace to Combine Applied DNA’s DNA tag-based Forensic Traceability and Authenticity with TruTrace's Industry Blockchain Hub to Deliver Unparalleled Tag-Test-Track Capabilit

  • Business Wire

    Molecular Tagging of Pharmaceutical Drugs Utilizing Applied DNA’s Technology Published in Peer-Reviewed Journal

    Applied DNA Sciences, Inc. (APDN), announced today that its scientific paper entitled, ‘Rapid authentication of pharmaceuticals via DNA tagging and field detection’, has been published in the June 2019 edition of PLOS ONE, detailing a novel Physical-Chemical Identifier (PCID) to authenticate and track legitimate pharmaceutical products through the pharmaceutical supply chain.

  • Business Wire

    Applied DNA Cannabis Partner TheraCann International Secures Agreement with South Africa’s House of Hemp

    Includes Implementation of TheraCann’s ETCH biotrace™ platform Utilizing Technology from Applied DNA

  • Business Wire

    Applied DNA and Integrated Supply Chain Partners Scale Up to Provide Global Material Traceability for Companies Declaring “2020” Sustainability Goals

    Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the “Company”), provides an update today on its accomplishments toward commercial-scale production to support global material traceability for companies declaring sustainability goals to be achieved by 2020. CertainT-verifiable products are now available through supply chain partners and brands, including Amazon and other e-commerce and retail stores, with outlook for growth as product flows to store shelves. The CertainT platform and forensic services were conceived to empower companies with the most advanced commercially-scalable and affordable technologies to help prove their compliance with stated sustainability goals.

  • Business Wire

    Applied DNA Closes the Loop on Traceability for Egyptian Pima with Genotyping Assays for Cotton Authentication

    Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), today announced that it has closed the loop on traceability for Egyptian Pima using DNA-based genotyping assays for cotton authentication. The Egyptian Pima developments join and expand a series of US Pima cotton assays performed within Applied DNA testing services and are based on work conducted over the past 3 years related to the validation of a known library of cotton cultivar standards.

  • Business Wire

    LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional Assay

    LineaRx, a wholly-owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced that it is in process of designing new, custom amplicons for an existing customer in the in vitro diagnostics market. The diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing revenue from an existing supply agreement. The company currently receives annual orders for large-scale DNA from this customer under a 5-year supply agreement executed in 2017.

  • Business Wire

    TheraCann and CannAcubed Enter Collaboration Agreement to Validate Cannabis and Hemp Supply Chain in China

    Applied DNA Sciences, Inc. (APDN), announced today that partner TheraCann International Benchmark Corporation (“TheraCann”), a leading full service international cannabis consultancy and technology firm, in conjunction CannAcubed Pte Ltd (CannAcubed), a pioneer in the China cannabis space with a focus on building the world’s largest diversified cannabis operations, has formed an agreement focused on the implementation of TheraCann’s molecular-tagging ETCH biotrace™ technology for the industrial hemp and cannabinoid markets in China.

  • Business Wire

    Applied DNA to Webcast 2019 Annual Stockholders’ Meeting

    Applied DNA Sciences, Inc. (APDN), will hold its 2019 Annual Meeting of Stockholders on Thursday, May 16, 2019. On that date, the company will provide an audio-only live webcast of the meeting beginning at 10:00 AM ET. Slide presentations accompanying the webcast will be available for download at that time on the ‘Events and Presentations’ portion of the ‘Investors’ page to the company’s website.

  • Associated Press

    Applied DNA Sciences: Fiscal 2Q Earnings Snapshot

    The Stony Brook, New York-based company said it had a loss of 8 cents per share. The DNA-based security technology company posted revenue of $778,500 in the period. Its adjusted revenue was $778,000. In ...

  • Business Wire

    Applied DNA Reports Fiscal Second Quarter 2019 Financial Results

    Company to Hold Conference Call and Webcast Today, Thursday, May 9, 2019 at 4:30 PM EST.

  • Business Wire

    A&E to Preview ‘Integrity’ Molecular-Tagged Thread Solution From Applied DNA Sciences at Texprocess

    Applied DNA Sciences, Inc. (APDN), announced today that American & Efird (A&E), a portfolio company of Elevate Textiles and the world’s foremost manufacturer and distributor of industrial and consumer sewing thread, embroidery thread and technical textiles, has announced it will be previewing its new line of advanced identification threads, branded “Integrity” later this month. A&E will publicly display this latest breakthrough at the upcoming Texprocess trade show in Frankfurt Germany.